ScholarIQanswers from OpenAlex & ORCID
Brian G. Feagan
ResearcherPublications, citations & collaboration network
Brian G. Feagan is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Brian G. Feagan have?
ScholarIQindexed works
Brian G. Feagan has 1,252 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Brian G. Feagan have?
ScholarIQcitation count
Brian G. Feagan has 91,864 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Brian G. Feagan?
ScholarIQh-index
Brian G. Feagan has an h-index of 137 in OpenAlex.
What is the i10-index of Brian G. Feagan?
ScholarIQi10-index
Brian G. Feagan has an i10-index of 521 in OpenAlex.
What is the ORCID of Brian G. Feagan?
ScholarIQorcid
The ORCID for Brian G. Feagan is on the source record.
What is the OpenAlex record for Brian G. Feagan?
ScholarIQopenalex
The OpenAlex for Brian G. Feagan is on the source record.
What are the most-cited papers on Brian G. Feagan?
ScholarIQmost cited works
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
Brian G. Feagan, Paul Rutgeerts, Bruce E. Sands, Stephen B. Hanauer, Jean‐Frédéric Colombel, William J. Sandborn, Gert Van Assche, Jeffrey Axler, Hyo Jong Kim, Silvio Danese, Irving H. Fox, Catherine Milch, Serap Sankoh, Tim Wyant, Jing Xu, Asit Parikh
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
Laurent Peyrin‐Biroulet, William J. Sandborn, Bruce E. Sands, Walter Reinisch, Willem A. Bemelman, Robert V. Bryant, Geert D’Haens, Iris Dotan, Marla C. Dubinsky, Brian G. Feagan, Gionata Fiorino, Richard B. Gearry, Suneeta Krishnareddy, Péter L. Lakatos, Edward V. Loftus, Philippe Marteau, Pia Munkholm, Travis B. Murdoch, Íngrid Ordás, Remo Panaccione, Robert H. Riddell, Joannie Ruel, David T. Rubin, Mark Samaan, Corey A. Siegel, Mark S. Silverberg, Jaap Stoker, S Schreiber, Simon Travis, Gert Van Assche, Silvio Danese, Julián Panés, Guillaume Bouguen, Sarah O’Donnell, Benjamin Pariente, Shawn Winer, Stephen B. Hanauer, J -F Colombel
Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
Brian G. Feagan, William J. Sandborn, Christopher Gasink, Douglas Jacobstein, Yinghua Lang, Joshua R. Friedman, Marion Blank, Jewel Johanns, Long-Long Gao, Miao Ye, Omoniyi J. Adedokun, Bruce E. Sands, Stephen B. Hanauer, Séverine Vermeire, Stephan R. Targan, Subrata Ghosh, Willem J. de Villiers, Jean–Frédéric Colombel, Zsolt Tulassay, Ursula Seidler, Bruce Salzberg, Pierre Desreumaux, Scott D. Lee, Edward V. Loftus, Levinus A. Dieleman, Seymour Katz, Paul Rutgeerts
Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis
William J. Sandborn, Chinyu Su, Bruce E. Sands, Geert D’Haens, Séverine Vermeire, Stefan Schreiber, Silvio Danese, Brian G. Feagan, Walter Reinisch, Wojciech Niezychowski, Gary S. Friedman, Nervin Lawendy, Dahong Yu, Deborah Woodworth, Arnab Mukherjee, Haiying Zhang, Paul J. Healey, Julián Panés
Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial
Wolfgang Hueber, Bruce E. Sands, Steve Lewitzky, Marc Vandemeulebroecke, Walter Reinisch, Peter Higgins, Jan Wehkamp, Brian G. Feagan, Michael Yao, Marek Karczewski, Jacek Karczewski, Nicole Pezous, Stephan Bek, Gerard Bruin, Bjoern Mellgard, C Berger, Marco Londei, Arthur P. Bertolino, Gervais Tougas, Simon Travis, for the Secukinumab in Crohn's Disease Study Group